IPC’s Pharmacovigilance Programmes complements CDSCO & Pharmexcil initiatives to fortify patient safety
In a concerted effort to bolster patient safety measures within the healthcare landscape, the Indian Pharmacopoeia Commission (IPC) is set to roll out its Skill Development Programmes on Pharmacovigilance. This initiative, designed to augment the existing capacity building efforts spearheaded by the Central Drugs Standard Control Organization (CDSCO) and the Pharmaceuticals Export Promotion Council of India (Pharmexcil), aims to cultivate a cadre of skilled professionals adept at ensuring the safe and efficacious use of pharmaceutical products.
Pharmexcil in collaboration with the CDSCO had recently hosted a capacity building programme in Goa with a renewed focus on generating awareness around pharmacovigilance practices. “As per the revised Schedule M norms notified last year in December, pharma companies are now mandated to set up Pharmacovigilance cells to ensure that drugs or medicines produced are safe and efficacious,” informed joint drug controller Dr S Eswara Reddy.
One of the IPC’s Pharmacovigilance Programme, which is scheduled to commence from June 3 to 7 2024, marks a significant milestone in India’s journey towards enhancing pharmacovigilance standards. It is poised to synergize with CDSCO’s ongoing initiatives aimed at strengthening pharmacovigilance infrastructure and fostering a culture of proactive monitoring and reporting of adverse drug reactions (ADRs). Additionally, the collaboration with Pharmexcil underscores a strategic partnership aimed at harnessing industry expertise to further bolster patient safety measures.
This comprehensive programme will cater to a diverse spectrum of stakeholders within the healthcare ecosystem, including pharmacy/Pharm D/MBBS/BDS/nursing students, young professionals in pharmacovigilance, pharmacists/nurses/doctors, academicians, industry professionals, and representatives from consumer organizations and NGOs. By providing participants with advanced training and practical insights into pharmacovigilance practices, the programme aims to empower them to contribute effectively towards enhancing patient safety standards.
Interested candidates are encouraged to complete their registration by the deadline on May 27, 2024, to secure their participation. Further details regarding registration guidelines and deadlines can be accessed through the IPC’s official website.
aningful progress. Through initiatives such as IPC’s Pharmacovigilance Programme, complemented by CDSCO and Pharmexcil’s capacity building efforts, the nation is poised to foster a safer and more resilient healthcare ecosystem, ultimately benefiting patients nationwide,” said Pharmexcil director general (DG) Uday Bhaskar. |
AuroBlog | Clinical Research Blog | Aurous HealthCare CRO, India 